Wang P, Liu X, Chen Y, Jun Hao E, Yao Z, Min Wen J, et al. Adult progenitor rejuvenation with embryonic factors. Cell Prolif. 2023;56:e13459 pubmed publisher

Ghosh M, Saha S, Li J, Montrose D, Martinez L. p53 engages the cGAS/STING cytosolic DNA sensing pathway for tumor suppression. Mol Cell. 2023;83:266-280.e6 pubmed publisher

Alalem M, Bhosale M, Ranjan A, Yamamoto S, Kaida A, Nishikawa S, et al. Mutant p53 Depletion by Novel Inhibitors for HSP40/J-Domain Proteins Derived from the Natural Compound Plumbagin. Cancers (Basel). 2022;14: pubmed publisher

Lama R, Xu C, Galster S, Querol Garc xed a J, Portwood S, Mavis C, et al. Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status. Front Oncol. 2022;12:933446 pubmed publisher

Dale K, Armond J, Hynds R, Vladimirou E. Modest increase of KIF11 expression exposes fragilities in the mitotic spindle, causing chromosomal instability. J Cell Sci. 2022;135: pubmed publisher

Li J, Lama R, Galster S, Inigo J, Wu J, Chandra D, et al. Small-Molecule MMRi62 Induces Ferroptosis and Inhibits Metastasis in Pancreatic Cancer via Degradation of Ferritin Heavy Chain and Mutant p53. Mol Cancer Ther. 2022;21:535-545 pubmed publisher

Gandhi N, Oturkar C, Das G. Estrogen Receptor-Alpha and p53 Status as Regulators of AMPK and mTOR in Luminal Breast Cancer. Cancers (Basel). 2021;13: pubmed publisher

Xia Y, Chen S, Cui J, Wang Y, Liu X, Shen Y, et al. Berberine suppresses bladder cancer cell proliferation by inhibiting JAK1-STAT3 signaling via upregulation of miR-17-5p. Biochem Pharmacol. 2021;188:114575 pubmed publisher

Ghosh M, Saha S, Bettke J, Nagar R, Parrales A, Iwakuma T, et al. Mutant p53 suppresses innate immune signaling to promote tumorigenesis. Cancer Cell. 2021;: pubmed publisher

Zheng C, Hu Y, Sakurai M, Pinzon Arteaga C, Li J, Wei Y, et al. Cell Competition Constitutes a Barrier for Interspecies Chimerism. Nature. 2021;: pubmed publisher

Cai J, Xia J, Zou J, Wang Q, Ma Q, Sun R, et al. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells. FEBS Open Bio. 2020;10:535-545 pubmed publisher

Shihabudeen Haider Ali M, Cheng X, Moran M, Haemmig S, Naldrett M, Alvarez S, et al. LncRNA Meg3 protects endothelial function by regulating the DNA damage response. Nucleic Acids Res. 2019;47:1505-1522 pubmed publisher

Bakht M, Derecichei I, Li Y, Ferraiuolo R, Dunning M, Oh S, et al. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocr Relat Cancer. 2018;26:131-146 pubmed publisher

Yang Hartwich Y, Tedja R, Roberts C, Goodner Bingham J, Cardenas C, Gurea M, et al. p53-Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT. Mol Cancer Res. 2019;17:153-164 pubmed publisher

Salari A, Thomay K, Lentes J, Ebersold J, Hagedorn M, Skawran B, et al. Effect of TP53 contact and conformational mutations on cell survival and erythropoiesis of human hematopoietic stem cells in a long term culture model. Oncotarget. 2018;9:29869-29876 pubmed publisher

Bernal A, Zafon E, Dominguez D, Bertran E, Tusell L. Generation of Immortalised But Unstable Cells after hTERT Introduction in Telomere-Compromised and p53-Deficient vHMECs. Int J Mol Sci. 2018;19: pubmed publisher

Bernal A, Moltó Abad M, Dominguez D, Tusell L. Acute telomere deprotection prevents ongoing BFB cycles and rampant instability in p16INK4a-deficient epithelial cells. Oncotarget. 2018;9:27151-27170 pubmed publisher

Karlin J, Allen J, Ahmad S, Hughes G, Sheridan V, Odedra R, et al. Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice. Mol Cancer Ther. 2018;17:1637-1647 pubmed publisher

Pascucci B, D Errico M, Romagnoli A, De Nuccio C, Savino M, Pietraforte D, et al. Overexpression of parkin rescues the defective mitochondrial phenotype and the increased apoptosis of Cockayne Syndrome A cells. Oncotarget. 2017;8:102852-102867 pubmed publisher

Milanovic M, Fan D, Belenki D, Däbritz J, Zhao Z, Yu Y, et al. Senescence-associated reprogramming promotes cancer stemness. Nature. 2018;553:96-100 pubmed publisher

Unno K, Roh M, Yoo Y, Al Shraideh Y, Wang L, Nonn L, et al. Modeling African American prostate adenocarcinoma by inducing defined genetic alterations in organoids. Oncotarget. 2017;8:51264-51276 pubmed publisher

Omar H, Tolba M, Hung J, Al Tel T. OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKC?/p53. Front Pharmacol. 2016;7:463 pubmed

Göllner S, Oellerich T, Agrawal Singh S, Schenk T, Klein H, Rohde C, et al. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. Nat Med. 2017;23:69-78 pubmed publisher

Meitinger F, Anzola J, Kaulich M, Richardson A, Stender J, Benner C, et al. 53BP1 and USP28 mediate p53 activation and G1 arrest after centrosome loss or extended mitotic duration. J Cell Biol. 2016;214:155-66 pubmed publisher

Benatti P, Basile V, Dolfini D, Belluti S, Tomei M, Imbriano C. NF-Y loss triggers p53 stabilization and apoptosis in HPV18-positive cells by affecting E6 transcription. Oncotarget. 2016;7:45901-45915 pubmed publisher

Salari A, Thomay K, Himmler K, Vajen B, Schienke A, Hagedorn M, et al. Establishing a murine xenograft-model for long-term analysis of factors inducing chromosomal instability in myelodysplastic syndrome: Pitfalls and successes. Cancer Genet. 2016;209:258-66 pubmed publisher

Salas E, Roy S, Marsh T, Rubin B, Debnath J. Oxidative pentose phosphate pathway inhibition is a key determinant of antimalarial induced cancer cell death. Oncogene. 2016;35:2913-22 pubmed publisher

Tripathi R, Ash D, Shaha C. Beclin-1-p53 interaction is crucial for cell fate determination in embryonal carcinoma cells. J Cell Mol Med. 2014;18:2275-86 pubmed publisher

Akita H, Marquardt J, Durkin M, Kitade M, Seo D, Conner E, et al. MYC activates stem-like cell potential in hepatocarcinoma by a p53-dependent mechanism. Cancer Res. 2014;74:5903-13 pubmed publisher

Godinho S, Picone R, Burute M, Dagher R, Su Y, Leung C, et al. Oncogene-like induction of cellular invasion from centrosome amplification. Nature. 2014;510:167-71 pubmed publisher

Akdemir K, Jain A, Allton K, Aronow B, Xu X, Cooney A, et al. Genome-wide profiling reveals stimulus-specific functions of p53 during differentiation and DNA damage of human embryonic stem cells. Nucleic Acids Res. 2014;42:205-23 pubmed publisher

Evangelou K, Bartkova J, Kotsinas A, Pateras I, Liontos M, Velimezi G, et al. The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis. Cell Death Differ. 2013;20:1485-97 pubmed publisher

Bhatt S, Ashlock B, Toomey N, Diaz L, Mesri E, Lossos I, et al. Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma. J Clin Invest. 2013;123:2616-28 pubmed publisher

Jackson T, Salmina K, Huna A, Inashkina I, Jankevics E, Riekstina U, et al. DNA damage causes TP53-dependent coupling of self-renewal and senescence pathways in embryonal carcinoma cells. Cell Cycle. 2013;12:430-41 pubmed publisher

Godar S, Ince T, Bell G, Feldser D, Donaher J, Bergh J, et al. Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell. 2008;134:62-73 pubmed publisher